Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33

Abstract 2827: Activity of the proprietary Hsp90 inhibitor IPI-493 in models of colorectal cancer correlates with RAS pathway activation

(2012) Kip A. West et al.   CANCER RESEARCH

STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability

(2012) T. Luo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers

(2011) Paul G. Richardson et al.   BRITISH JOURNAL OF HAEMATOLOGY

STK33 Kinase Activity Is Nonessential in KRAS-Dependent Cancer Cells

(2011) C. Babij et al.   CANCER RESEARCH

HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab

(2011) S. Modi et al.   CLINICAL CANCER RESEARCH

Towards systematic functional characterization of cancer genomes

(2011) Jesse S. Boehm et al.   NATURE REVIEWS GENETICS

The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models

(2011) E Normant et al.   ONCOGENE

Response and determinants of cancer cell susceptibility to PI3K inhibitors: Combined targeting of PI3K and Mek1 as an effective anticancer strategy

(2010) Ker Yu et al.   CANCER BIOLOGY & THERAPY

A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma

(2010) Marta Puyol et al.   CANCER CELL

PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling

(2010) E. Halilovic et al.   CANCER RESEARCH

HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans

(2010) Sachie Marubayashi et al.   JOURNAL OF CLINICAL INVESTIGATION

Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models

(2010) Silvestre Vicent et al.   JOURNAL OF CLINICAL INVESTIGATION

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer

(2010) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Personalized Medicine in Non–Small-Cell Lung Cancer: IsKRASa Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy?

(2010) Patrick J. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer

(2010) Alberto Bardelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Translating cancer research into targeted therapeutics

(2010) J. S. de Bono et al.   NATURE

International network of cancer genome projects

(2010) Thomas J. Hudson (Chairperson) et al.   NATURE

HSP90 at the hub of protein homeostasis: emerging mechanistic insights

(2010) Mikko Taipale et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells

(2010) Y Wang et al.   ONCOGENE

Targeting HSP90 for cancer therapy

(2009) D Mahalingam et al.   BRITISH JOURNAL OF CANCER

A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival

(2009) Anurag Singh et al.   CANCER CELL

PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers

(2009) S. Wee et al.   CANCER RESEARCH

Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells

(2009) Claudia Scholl et al.   CELL

A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene

(2009) Ji Luo et al.   CELL

Purine-Scaffold Hsp90 Inhibitors

(2009) Tony Taldone et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Update on Hsp90 Inhibitors in Clinical Trial

(2009) Y. Kim et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions

(2009) Martin L. Sos et al.   JOURNAL OF CLINICAL INVESTIGATION

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

(2009) David A. Barbie et al.   NATURE

The cancer genome

(2009) Michael R. Stratton et al.   NATURE

Perspectives on the development of imatinib and the future of cancer research

(2009) Brian J Druker   NATURE MEDICINE

A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6–dependent B cell lymphomas

(2009) Leandro C Cerchietti et al.   NATURE MEDICINE

Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models

(2009) E. Caldas-Lopes et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibition of Hsp90 Down-regulates Mutant Epidermal Growth Factor Receptor (EGFR) Expression and Sensitizes EGFR Mutant Tumors to Paclitaxel

(2008) A. Sawai et al.   CANCER RESEARCH

The Heat Shock Protein 90 Chaperone Complex: An Evolving Therapeutic Target

(2008) M. Barginear et al.   CURRENT CANCER DRUG TARGETS

Targeting Hsp90: small-molecule inhibitors and their clinical development

(2008) Tony Taldone et al.   CURRENT OPINION IN PHARMACOLOGY

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

(2008) Jeffrey A Engelman et al.   NATURE MEDICINE

Ras oncogenes: split personalities

(2008) Antoine E. Karnoub et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY